Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Medicus Pharma Ltd ( (MDCX) ).
Medicus Pharma has submitted an optimized Phase 2 clinical study protocol to the U.S. Food and Drug Administration for Teverelix, its investigational GnRH antagonist, to prevent recurrent acute urinary retention in men with benign prostatic hyperplasia. The trial, led by urology expert Dr. Steven Kaplan, focuses on a mechanism-driven primary endpoint and aims to generate early pharmacodynamic data within 12 weeks.
The redesigned study reduces the planned patient enrollment to about 126 men across the U.S. and Europe, representing roughly a three-fold decrease from the original plan and a meaningful cut in development costs. By emphasizing capital efficiency, a clear prostate volume reduction signal, and an interim analysis to guide dose and route decisions, Medicus is positioning Teverelix for faster development, earlier partnering opportunities, and potential entry into an underserved AUR recurrence market estimated at approximately $2 billion.
The most recent analyst rating on (MDCX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily held down by weak financial performance, driven by no revenue, widening operating losses, and sharply increasing cash burn that implies ongoing external funding needs, alongside balance-sheet equity volatility. Technicals are also negative with a strong downtrend (price below all key moving averages and negative MACD), only partially tempered by oversold readings. Valuation metrics provide little support because the P/E is not meaningful and no dividend yield is available.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a Nasdaq-listed precision-guided biotech and life sciences company focused on accelerating the clinical development of novel and potentially disruptive therapeutic assets. The company operates across multiple countries on three continents, targeting areas of significant unmet medical need in urology and other specialties.
Average Trading Volume: 3,899,890
Technical Sentiment Signal: Sell
Current Market Cap: $17.59M
See more data about MDCX stock on TipRanks’ Stock Analysis page.